H.C. Wainwright upgraded Prelude Therapeutics to Buy from Neutral with an unchanged price target of $5. The recent stock decline provides an attractive entry point, the analyst tells investors in a research note. The firm says Prelude shares are trading at a “very modest” enterprise value of roughly $5M despite having a portfolio of assets in active development and multiple upcoming catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics reports results from Phase 1 trial of PRT3789
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
- Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
- Prelude Therapeutics announces publication of abstract on PRT3789
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024